General Information of Drug Therapeutic Target (DTT) (ID: TTL69WB)

DTT Name Angiotensin-converting enzyme (ACE)
Synonyms Kininase II; Dipeptidyl carboxypeptidase I; DCP1; DCP; CD143 antigen; CD143; ACE
Gene Name SLC33A1
DTT Type
Successful target
[1]
BioChemical Class
Glycosylase
UniProt ID
ACE_HUMAN
TTD ID
T82577
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 3.2.1.-
Sequence
MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQV
LFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRI
IGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSR
SYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDL
EHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPF
PDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCH
ASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAI
GDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFS
GRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQF
HEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLL
KYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTS
QVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRI
IKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKY
EDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLER
LFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPS
APSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHAS
AWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGD
VLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGS
ITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHE
ALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSY
FKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQW
LLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS
Function
Able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin.
KEGG Pathway
Renin-angiotensin system (hsa04614 )
Chagas disease (American trypanosomiasis) (hsa05142 )
Hypertrophic cardiomyopathy (HCM) (hsa05410 )
Reactome Pathway
Metabolism of Angiotensinogen to Angiotensins (R-HSA-2022377 )
BioCyc Pathway
MetaCyc:HS08412-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
20 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alacepril DML6SRO Cardiovascular disease BA00-BE2Z Approved [2]
Benazepril DMH1M9B Hypertension BA00-BA04 Approved [3]
Captopril DM458UM Chronic heart failure BD1Z Approved [4]
Cilazapril DM4V6JA Congestive heart failure BD10 Approved [5]
Delapril DM7EUK3 Cardiovascular disease BA00-BE2Z Approved [2]
Deserpidine DMRH7CV Hypertension BA00-BA04 Approved [1]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [6]
Enalaprilat DMFYAM1 Congestive heart failure BD10 Approved [7]
Fosinopril DM9NJ52 Chronic heart failure BD1Z Approved [8]
Hydrochlorothiazide DMUSZHD Chronic heart failure BD1Z Approved [9]
Imidapril DMUL7T1 Cardiovascular disease BA00-BE2Z Approved [2]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [10]
Moexipril DM26E4B Hypertension BA00-BA04 Approved [11]
Perindopril DMOPZDT Hypertension BA00-BA04 Approved [12]
Quinapril DMR8H31 Chronic heart failure BD1Z Approved [13]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [14]
Rescinnamine DMG7SQK Hypertension BA00-BA04 Approved [15]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [16]
Temocapril hydrochloride DM0JXFL Cardiovascular disease BA00-BE2Z Approved [2]
Trandolapril DM4L6EU Chronic heart failure BD1Z Approved [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Approved Drug(s)
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CONTIGOSIDE B DMX9V8K Thrombosis DB61-GB90 Phase 2/3 [18]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [19]
GW-796406 DMQ46DN Hypotension BA20-BA21 Phase 1 [19]
------------------------------------------------------------------------------------
14 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ilepatril DMTR50E Diabetic nephropathy GB61.Z Discontinued in Phase 2/3 [20]
Ceronapril DMFBNI6 Major depressive disorder 6A70.3 Discontinued in Phase 2 [21]
Idrapril DM7O0UR Hypertension BA00-BA04 Discontinued in Phase 2 [22]
M-100240 DMQ1LWU Hypotension BA20-BA21 Discontinued in Phase 2 [23]
METIAPRIL DM90SHY Hypotension BA20-BA21 Discontinued in Phase 2 [24]
UTIBAPRIL DMOB2K5 Hypertension BA00-BA04 Discontinued in Phase 2 [25]
Zabiciprilat DMBSHJ6 Hypertension BA00-BA04 Discontinued in Phase 2 [26]
BMS-182657 DM0K4DZ Cardiovascular disease BA00-BE2Z Terminated [27]
CGS-30440 DM94WIO Hypertension BA00-BA04 Terminated [28]
DU-1777 DM87ZWP Hypertension BA00-BA04 Terminated [29]
GW-660511 DMG5A1Z Hypertension BA00-BA04 Terminated [30]
Omapatrilat DMAGUY0 Hypertension BA00-BA04 Terminated [31]
SCH-54470 DMEWLZ7 N. A. N. A. Terminated [32]
SQ-26332 DM6SW2R N. A. N. A. Terminated [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Discontinued Drug(s)
16 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose DMOUG6Y Discovery agent N.A. Investigative [34]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [34]
ASTRAGALIN DMZHWPG Discovery agent N.A. Investigative [18]
BRL-36378 DMRI49D Discovery agent N.A. Investigative [35]
BUTEIN DM8E54P Discovery agent N.A. Investigative [36]
fasidotrilat DMC8G7X Discovery agent N.A. Investigative [37]
Kaempferol-3-O-(2''-O-galloyl)-glucoside DMUCZ3F Discovery agent N.A. Investigative [18]
lisinopril-tryptophan DMQ42KU Discovery agent N.A. Investigative [38]
LY-292223 DML36ZE Discovery agent N.A. Investigative [39]
moexiprilat DMPYBHI Discovery agent N.A. Investigative [40]
N-Carboxymethyl-N-cyclopentyl-phthalamic acid DME9U7Y Discovery agent N.A. Investigative [41]
RB-105 DMRK3HO Hypertension BA00-BA04 Investigative [42]
RIP DM83L5Y Discovery agent N.A. Investigative [43]
RJM-0035-K002 DM2P6I8 Hypertension BA00-BA04 Investigative [44]
RXP-407 DMM5O30 Discovery agent N.A. Investigative [45]
[Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid DMQ8CD3 Discovery agent N.A. Investigative [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Major depressive disorder 6A20 Pre-frontal cortex 2.62E-01 -0.01 -0.06
------------------------------------------------------------------------------------

References

1 Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906.
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
4 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
5 Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93.
6 Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
7 Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
8 Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
11 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
12 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
13 An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50.
14 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
15 Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51.
16 Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
17 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
18 Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3.
19 Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
20 Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9.
21 Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers. Ther Drug Monit. 1992 Jun;14(3):209-19.
22 Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992 Jul;20(1):139-46.
23 Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiot... J Cardiovasc Pharmacol. 1998 Mar;31(3):408-17.
24 The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure. Klin Med (Mosk). 1995;73(3):49-51.
25 Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91.
26 Enzyme immunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite in human plasma: application to pharmacokinetic studies. Ther Drug Monit. 1993 Oct;15(5):448-54.
27 Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.
28 Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998 Mar;284(3):974-82.
29 Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models. Arzneimittelforschung. 1995 Aug;45(8):853-8.
30 The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000 Feb;129(4):671-80.
31 Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5.
32 Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20.
33 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
34 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
35 Antihypertensive and angiotensin converting enzyme inhibitory activities of a novel dihydrobenzofuran analogue. Arzneimittelforschung. 1988 Apr;38(4):531-6.
36 The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1990-3.
37 Protease inhibitors in the clinic. Med Chem. 2005 Jan;1(1):71-104.
38 Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J. 2010 Apr 28;428(1):67-74.
39 Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem. 2005 Jan 27;48(2):483-98.
40 Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63.
41 Angiotensin converting enzyme inhibitors. (Mercaptoaroyl)amino acids. J Med Chem. 1985 Mar;28(3):328-32.
42 Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55.
43 Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors. J Med Chem. 1985 Nov;28(11):1553-5.
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1613).
45 New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme. Biol Chem. 2012 May;393(6):485-93.